Cabaletta Bio, Inc.: directors' dealings · United States · SEC (Form 4)

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ in the United States (United States), focused on developing targeted cell therapies for autoimmune diseases. Founded in 2017 and emerging from the University of Pennsylvania, the company is headquartered in Philadelphia, Pennsylvania. Its origin story matters strategically: Cabaletta was built around translating academic immunology and cell-therapy expertise into a platform aimed at delivering durable, potentially curative treatment responses rather than long-term symptom control. ([cabalettabio.com](https://www.cabalettabio.com/about?utm_source=openai)) The company’s lead asset is rese-cel (resecabtagene autoleucel), an autologous CD19-directed CAR-T therapy designed to deplete pathogenic B cells and reset immune dysfunction in autoimmune disease. Cabaletta is advancing rese-cel through its RESET (REstoring SElf-Tolerance) clinical development program, which spans multiple disease areas including systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. This gives the company a platform-like strategy: one product concept, multiple indications, and the potential for cross-indication clinical and commercial leverage. At the same time, this also means the investment case remains highly dependent on clinical readouts, regulatory alignment, and manufacturing execution. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai)) From a competitive standpoint, Cabaletta occupies a differentiated niche. It is one of the more focused developers applying CAR-T to autoimmune disease, a segment that remains far less crowded than oncology but also far less proven commercially. The company has been emphasizing practical treatment advantages such as a favorable safety profile that may support outpatient use, along with a manufacturing model intended to improve scalability and capital efficiency. In April 2026, Cabaletta announced a 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel, which is an important step toward potential launch readiness and supply-chain de-risking. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/145/cabaletta-bio-and-cellares-announce-10-year-commercial?utm_source=openai)) Operationally, Cabaletta’s footprint is centered in Philadelphia, with clinical activity concentrated in the United States and supporting international visibility through scientific conferences and select trial activity in Europe. Recent company updates in 2025 and 2026 show a business moving from pure R&D toward more explicit pre-commercial planning: new clinical datasets have been presented, 2026 strategic priorities were outlined, and management reiterated a target of a BLA submission in 2027 for myositis. For investors, CABA represents a high-risk, high-upside U.S. NASDAQ biotech story anchored in autoimmune cell therapy innovation, but still subject to the binary nature of late-stage development outcomes. ([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai))